A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

This study tests an octreotide injection for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) — slow-growing tumors that start in the pancreas or gut and release hormones. Octreotide mimics a natural hormone to slow tumor growth. The study assesses how effective and safe this treatment is in this patient population. **You may be eligible if...** - You are 18 or older with histologically confirmed advanced GEP-NET - Your tumor shows uptake on a somatostatin receptor scan - You have measurable disease on imaging - You have received no more than 2 prior systemic therapies - Your blood counts and organ function are adequate - You are expected to live more than 3 months **You may NOT be eligible if...** - You have received more than 2 prior systemic treatments - You have poor liver function or very abnormal blood counts - You are pregnant or not using contraception - You have serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.